Case series finds no adverse reaction to tecovirimat in four pregnant persons with mpox
Is the mpox treatment safe for pregnant people? Early data shows no adverse reactions
A U.S. surveillance case series of mpox in cisgender women reported no adverse reaction to tecovirimat in four treated pregnant persons.
Early data on pregnant people treated for mpox shows no adverse reactions to the antiviral drug tecovirimat, offering a small but valuable p…
ACIP Recommends JYNNEOS Vaccine for Adults at Risk During Mpox Outbreaks
Health Panel Recommends Mpox Vaccine for At-Risk Adults During Outbreaks
A 2023 ACIP recommendation report advises use of the JYNNEOS vaccine for persons aged 18 years and older at risk for mpox during an outbreak…
U.S. health experts now recommend the JYNNEOS vaccine for adults at risk of mpox during outbreaks to help protect public health.
Paediatric mpox PCR positivity rates range from 6.95% to 35.6% in global systematic review
How does mpox affect children? New review finds wide range in positive tests
A systematic review and meta-analysis of 22 studies on paediatric mpox globally found PCR positivity rates ranging from 6.95% in non-endemic…
Mpox test positivity in children ranges from 7% to 36%, with younger kids facing higher risks of severe complications like fever and skin le…